The	O
impact	O
of	O
tracheal	B-Multi-tissue_structure
intubation	O
on	O
host	O
defenses	O
and	O
risks	O
for	O
nosocomial	O
pneumonia	O
.	O

Nosocomial	O
pneumonia	O
remains	O
a	O
common	O
complication	O
in	O
patients	O
treated	O
with	O
endotracheal	B-Immaterial_anatomical_entity
intubation	O
and	O
mechanical	O
ventilation	O
and	O
continues	O
to	O
have	O
a	O
significant	O
impact	O
on	O
the	O
mortality	O
rate	O
of	O
these	O
patients	O
.	O

Epidemiologic	O
studies	O
have	O
shown	O
that	O
the	O
risk	O
of	O
pneumonia	O
increases	O
with	O
the	O
duration	O
of	O
intubation	O
but	O
that	O
the	O
period	O
of	O
highest	O
risk	O
is	O
the	O
first	O
2	O
weeks	O
of	O
therapy	O
.	O

Gram	O
-	O
negative	O
bacteria	O
account	O
for	O
most	O
nosocomial	O
pneumonias	O
in	O
intubated	O
patients	O
,	O
but	O
Staphylococcus	O
aureus	O
may	O
also	O
play	O
a	O
role	O
in	O
what	O
may	O
be	O
a	O
polymicrobial	O
infection	O
.	O

In	O
the	O
most	O
seriously	O
ill	O
individuals	O
,	O
and	O
in	O
those	O
treated	O
with	O
long	O
-	O
term	O
mechanical	O
ventilation	O
,	O
Pseudomonas	O
aeruginosa	O
is	O
a	O
common	O
pathogen	O
.	O

Endotracheal	B-Immaterial_anatomical_entity
intubation	O
and	O
mechanical	O
ventilation	O
predispose	O
to	O
pneumonia	O
for	O
a	O
variety	O
of	O
reasons	O
(	O
see	O
Fig	O
.	O
1	O
)	O
.	O

The	O
endotracheal	B-Multi-tissue_structure
tube	I-Multi-tissue_structure
can	O
have	O
direct	O
effects	O
on	O
the	O
airway	B-Multi-tissue_structure
that	O
result	O
in	O
a	O
reduction	O
in	O
local	O
host	O
defenses	O
.	O

Thus	O
,	O
mucosal	B-Multi-tissue_structure
injury	O
can	O
reduce	O
mucociliary	B-Tissue
function	O
,	O
while	O
upper	O
airway	B-Multi-tissue_structure
defenses	O
are	O
bypassed	O
and	O
the	O
effectiveness	O
of	O
cough	O
is	O
reduced	O
.	O

Indirectly	O
,	O
intubation	O
can	O
result	O
in	O
an	O
enhanced	O
capacity	O
of	O
tracheobronchial	B-Cell
cells	I-Cell
to	O
bind	O
gram	O
-	O
negative	O
bacteria	O
,	O
an	O
effect	O
that	O
favors	O
airway	B-Multi-tissue_structure
colonization	O
and	O
pneumonia	O
.	O

The	O
injury	O
to	O
the	O
airway	B-Multi-tissue_structure
can	O
create	O
binding	O
sites	O
for	O
bacteria	O
in	O
the	O
basement	B-Cellular_component
membrane	I-Cellular_component
of	O
the	O
bronchial	B-Multi-tissue_structure
tree	I-Multi-tissue_structure
and	O
the	O
stimulation	O
of	O
the	O
secretion	O
of	O
mucus	B-Organism_substance
,	O
which	O
then	O
stagnates	O
and	O
can	O
create	O
potential	O
sites	O
for	O
bacterial	O
adherence	O
.	O

The	O
endotracheal	B-Multi-tissue_structure
tube	I-Multi-tissue_structure
also	O
enhances	O
bacterial	O
entry	O
to	O
the	O
lung	B-Organ
by	O
serving	O
as	O
a	O
reservoir	O
for	O
bacteria	O
to	O
remain	O
sequestered	O
,	O
safe	O
from	O
host	O
defenses	O
.	O

Respiratory	B-Anatomical_system
therapy	O
devices	O
can	O
allow	O
bacteria	O
to	O
proliferate	O
and	O
can	O
then	O
introduce	O
them	O
into	O
the	O
patient	O
if	O
not	O
handled	O
properly	O
.	O

Finally	O
,	O
patients	O
who	O
are	O
ill	O
enough	O
to	O
require	O
intubation	O
also	O
have	O
disease	O
-	O
associated	O
impairments	O
in	O
systemic	O
host	O
defense	O
,	O
which	O
add	O
to	O
the	O
impairments	O
caused	O
by	O
the	O
use	O
of	O
an	O
artificial	O
airway	B-Multi-tissue_structure
.	O

The	O
host	O
defense	O
impairments	O
that	O
occur	O
in	O
mechanically	O
ventilated	O
patients	O
can	O
lead	O
to	O
respiratory	B-Organism_subdivision
tract	I-Organism_subdivision
infection	O
in	O
the	O
form	O
of	O
either	O
febrile	O
tracheobronchitis	O
or	O
pneumonia	O
.	O

The	O
diagnosis	O
of	O
pneumonia	O
in	O
intubated	O
patients	O
is	O
difficult	O
and	O
controversial	O
.	O

It	O
can	O
be	O
made	O
by	O
either	O
clinical	O
criteria	O
or	O
microbiologic	O
criteria	O
,	O
the	O
latter	O
by	O
using	O
a	O
bronchoscopically	O
directed	O
protected	O
specimen	O
brush	O
.	O

Therapy	O
of	O
pneumonia	O
in	O
mechanically	O
ventilated	O
patients	O
is	O
not	O
always	O
successful	O
,	O
and	O
systemic	O
antibiotics	O
may	O
need	O
to	O
be	O
supplemented	O
by	O
topical	O
antimicrobials	O
.	O

No	O
clearly	O
effective	O
prophylactic	O
strategy	O
currently	O
exists	O
,	O
but	O
our	O
understanding	O
of	O
pneumonia	O
pathogenesis	O
has	O
led	O
to	O
some	O
promising	O
directions	O
.	O

As	O
more	O
data	O
are	O
collected	O
,	O
inhaled	O
antibiotics	O
,	O
selective	O
digestive	O
decontamination	O
,	O
and	O
enhancement	O
of	O
host	O
defenses	O
by	O
cytokines	O
and	O
pre	O
-	O
formed	O
antibodies	O
may	O
emerge	O
as	O
useful	O
approaches	O
.	O

